✨ Free AI Report
Entrada Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Entrada Therapeutics, Inc.
Company Research

Entrada Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Entrada Therapeutics, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Early-stage biotech with potentially transformative intracellular delivery technology and multiple near-term clinical catalysts in a high-unmet-need DMD market. The company expects Phase 1/2 data readouts in Q2 2026 for Cohort 1 and year-end for Cohort 2 of its lead DMD program. Recent positive DMC recommendations to escalate dosing support.

What is Entrada Therapeutics, Inc.'s industry? Entrada Therapeutics, Inc. (entradatx.com) operates in Clinical-stage biopharmaceutical (rare neuromuscular and ocular diseases). AskCyborg classifies Entrada Therapeutics, Inc. under Clinical-stage biopharmaceutical (rare neuromuscular and ocular diseases) in its company registry.

Entrada Therapeutics is a clinical-stage biopharmaceutical company developing Endosomal Escape Vehicle (EEV)-therapeutics designed to enable efficient intracellular delivery of therapeutics into various organs and tis...

6/ 10Solid

Cyborg Score thesis

Early-stage biotech with potentially transformative intracellular delivery technology and multiple near-term clinical catalysts...

Read the full analyst-debate transcript →
Industry Clinical-stage biopharmaceutical (rare neuromuscular and ocular diseases)
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Entrada Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Entrada Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Entrada Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Entrada Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Entrada Therapeutics, Inc. Overview

Pro stress-test →

Entrada Therapeutics is a clinical-stage biopharmaceutical company developing Endosomal Escape Vehicle (EEV)-therapeutics designed to enable efficient intracellular delivery of therapeutics into various organs and tissues. The company is advancing RNA- and protein-based programs for neuromuscular and ocular diseases.

Strategic Profile

Pro stress-test →

Entrada's primary focus is Duchenne muscular dystrophy (DMD), with Phase 1/2 studies of ENTR-601-44 and ENTR-601-45, and planned development of ENTR-601-50 and ENTR-601-51. The company gained FDA Rare Pediatric Disease Designation for ENTR-601-44 and ended 2025 with $295.7M in cash with runway into Q3 2027.

Competitive Landscape

Pro stress-test →

In the rare disease biotech space, Entrada competes alongside companies such as Kymera Therapeutics, Kodiak Sciences, and other clinical-stage biopharma firms. Entrada's proprietary EEV technology provides differentiation in intracellular drug delivery, a less crowded segment compared to traditional monoclonal antibodies or small molecules, positioning it uniquely for intracellular target engagement.

Industry Context

Entrada Therapeutics, Inc. operates in Clinical-stage biopharmaceutical (rare neuromuscular and ocular diseases).

Key facts

Founded: 2016 · Headquarters: Boston, Massachusetts · Employees: null · Revenue: Minimal (collaboration-dependent) · Market cap: $456M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Entrada Therapeutics, Inc..

  • Independent DMC recommended dose escalation in ELEVATE-44-201 to 12 mg/kg with Cohort 1 data expected Q2 2026 and Cohort 2 data by year-end.
  • FDA granted Rare Pediatric Disease Designation to ENTR-601-44 in December 2025, providing potential regulatory advantages.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 26, 2026Q4 2025 and full-year results reported with DMC recommendation for ELEVATE-44-201 Cohort 2 dose escalation to 12 mg/kg and ENTR-801 nomination for USH2A.
  • December 2025FDA granted Rare Pediatric Disease Designation to ENTR-601-44.
  • +1 moreTrack every material event for Entrada Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Entrada Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Intracellular therapeuticsTargeted protein degradation→Ocular/retinal diseasesAnti-VEGF biologics for wet AMD→RNA-based therapeuticsGenetic medicine for myotonic dystrophy→

Compare Entrada Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Entrada Therapeutics, Inc. operates in Clinical-stage biopharmaceutical (rare neuromuscular and ocular diseases). See how the rest of the sector scores on the Cyborg framework.

Browse Clinical-stage biopharmaceutical (rare neuromuscular and ocular diseases) research →
NEW · MCP server

Ask your AI assistant about Entrada Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Entrada Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Entrada Therapeutics, Inc. do this quarter?”
“Is Entrada Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Entrada Therapeutics, Inc. do?+
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing Endosomal Escape Vehicle (EEV)-therapeutics designed to enable efficient intracellular delivery of therapeutics into various organs and tis...
What is Entrada Therapeutics, Inc.'s Cyborg Score?+
Entrada Therapeutics, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Entrada Therapeutics, Inc.'s main competitors?+
Named competitors include Intracellular therapeutics, Ocular/retinal diseases, RNA-based therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Entrada Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Entrada Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Entrada Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.